Corpus Intelligence IC Memo — NICHOLAS H. NOYES MEMORIAL HOSPITAL 2026-04-26 12:35 UTC
IC Memo — NICHOLAS H. NOYES MEMORIAL HOSPITAL
Investment Committee Memorandum | NY | 67 beds | Grade C | EBITDA uplift $5.5M
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

NICHOLAS H. NOYES MEMORIAL HOSPITAL

CCN 330238 | LIVINGSTON, NY | 67 beds | April 26, 2026
EBITDA BridgeData Room
C
Investability

1. Target Overview & Investment Thesis

NICHOLAS H. NOYES MEMORIAL HOSPITAL is a 67-bed under-performing / distressed in LIVINGSTON, NY with $74.3M in net patient revenue and a -10.7% operating margin. The hospital serves a payer mix of 25.6% Medicare, 1.5% Medicaid, and 72.9% commercial.

Thesis: Turnaround. Our ML models identify $5.5M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from -10.7% to -3.3% (+736bps).

Net Revenue HCRIS$74.3M
Current EBITDA COMPUTED$-8.0M
Operating Margin COMPUTED-10.7%
Occupancy HCRIS40.7%
Revenue / Bed COMPUTED$1.1M
Net-to-Gross HCRIS38.9%
Distress Probability ML50.6%

2. Market Context & Competitive Position

196
NY Hospitals
-17.5%
State Median Margin
48
Comparable Hospitals

NY has 196 Medicare-certified hospitals with a median operating margin of -17.5%. The target's margin of -10.7% places it above the state median. Among 48 size-comparable peers (34-134 beds), the median margin is -15.1%. The target performs in line with or above peers.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (34-134), prioritizing same-state peers. 48 hospitals in the comp set.

HospitalStateBedsRevenueMargin
NICHOLAS H. NOYES MEMORIAL HOS (Target)NY67$74.3M-10.7%
CAYUGA MEDICAL CENTER AT ITHACNY107$302.3M-13.1%
PECONIC BAY MEDICAL CENTERNY130$294.3M-9.3%
NEW YORK PRESBYTERIAN HUDSON VNY128$249.3M-9.5%
CANTON-POTSDAM HOSPITALNY94$231.6M-5.7%
EPISCOPAL HEALTH SERVICESNY126$214.7M-50.0%
ST. JOSEPHS MEDICAL CENTERNY106$212.9M-24.1%
FREDRICK FERRIS THOMPSON HOSPINY113$197.8M-9.0%
NORTH CENTRAL BRONXNY130$188.2M-26.5%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $5.5M (736bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$1.6M+210bp18mo
Cost to Collect4.5%2.5%$1.5M+200bp12mo
Denial Rate Reduction12.0%6.5%$1.5M+198bp12mo
A/R Days Reduction5200.0%3800.0%$904K+122bp9mo
Clean Claim Rate88.0%96.0%$48K+6bp6mo

5. EBITDA Bridge

Net Collection Rate
$1.6M
Cost to Collect
$1.5M
Denial Rate Reduction
$1.5M
A/R Days Reduction
$904K
Clean Claim Rate
$48K
Total EBITDA Uplift$5.5M
Current EBITDA$-8.0M
+ RCM Uplift+$5.5M
Pro Forma EBITDA$-2.5M
Current Margin-10.7%
Pro Forma Margin-3.3%
WC Released (1x)$2.8M

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$-12.2M$2.2M0.00x-100.0%
Base (11x exit)10.0x11.0x$-12.2M$-1.5M0.00x-100.0%
Bull Case9.0x11.0x$-11.0M$12.5M0.00x-100.0%
Bull (12x exit)9.0x12.0x$-11.0M$10.4M0.00x-100.0%
Bear Case11.0x10.0x$-13.5M$-21.1M0.00x-100.0%
Bear (11x exit)11.0x11.0x$-13.5M$-27.6M0.00x-100.0%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
HighNegative operating marginRCM uplift bridge shows clear path to profitability; working capital release provides near-term cash cushion
HighElevated distress probabilityModel estimates 50.6% probability of financial distress. Mitigant: distressed entry pricing (7-9x) compensates for risk

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 48 hospitals with 34-134 beds
  • Same-state prioritization (n=49)
  • Comp margins: P25=-27.8% / P50=-15.1% / P75=-9.3%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.